Switch to Anabolic Therapy Immediately
This patient requires immediate transition from bisphosphonate to anabolic therapy with teriparatide or abaloparatide for up to 2 years, followed by denosumab (not another bisphosphonate) to prevent rebound bone loss. She has sustained a hip fracture while on adequate bisphosphonate therapy (Actonel/risedronate), which defines her as having "very high fracture risk" and represents treatment failure 1.
Why This Patient Needs Anabolic Therapy Now
This 76-year-old woman meets multiple criteria for very high fracture risk:
- Hip fracture while on bisphosphonate therapy = treatment failure 1
- Age 76 with multiple cardiovascular risk factors
- Elevated alkaline phosphatase (178) at 6 weeks post-fracture suggests either ongoing fracture healing or high bone turnover that bisphosphonates failed to control
The Endocrine Society guidelines explicitly recommend teriparatide or abaloparatide for postmenopausal women at very high fracture risk, particularly those with severe or multiple vertebral fractures 1. While she has a hip fracture rather than vertebral fractures, fracturing while on bisphosphonate therapy places her in the same very high-risk category.
Specific Treatment Algorithm
Step 1: Initiate Anabolic Therapy (Choose One)
Teriparatide 20 mcg subcutaneous daily OR Abaloparatide 80 mcg subcutaneous daily for up to 2 years 2
- Abaloparatide shows greater BMD gains at the femoral neck and total hip compared to teriparatide 2
- Both reduce vertebral fractures by 74-87% and nonvertebral fractures by 39-46% 1
- Abaloparatide does not require refrigeration after opening 2
Before starting, check:
- Serum calcium, PTH, 25(OH)D, and alkaline phosphatase to rule out hyperparathyroidism or Paget's disease 2
- Ensure adequate vitamin D repletion (target 25(OH)D >30 ng/mL)
Step 2: Critical Cardiovascular Considerations
DO NOT use romosozumab in this patient. Despite its superior efficacy, romosozumab carries a black-box warning against use in patients with recent MI or stroke or at high cardiovascular risk 2. This patient has:
- CAC score 292 (moderate coronary atherosclerosis)
- History of AAA
- Factor V Leiden (thrombophilia)
- Active smoking
- Family history of stroke
The ARCH trial showed increased serious cardiovascular events with romosozumab versus alendronate 2, making it contraindicated here despite her very high fracture risk.
Step 3: Sequential Therapy After Anabolic Treatment
After completing 2 years of teriparatide or abaloparatide, transition immediately to denosumab 60 mg subcutaneous every 6 months 1, 2.
Why denosumab rather than returning to bisphosphonates:
- She already failed bisphosphonate therapy
- Denosumab provides superior antiresorptive effect to maintain anabolic gains 2
- No "washout period" needed between anabolic and antiresorptive therapy 2
- Studies show alendronate after abaloparatide maintains gains, but she needs stronger therapy given her treatment failure 2
Critical denosumab management:
- Must be given exactly every 6 months—never delay or skip doses 1
- Stopping denosumab without transition to another antiresorptive causes rapid bone loss and rebound vertebral fractures within 6-24 months 1
- If denosumab must be stopped, immediately transition to bisphosphonate or other antiresorptive 1
Addressing the Elevated Alkaline Phosphatase
The alkaline phosphatase of 178 at 6 weeks post-fracture requires interpretation:
- Expected: Bone-specific alkaline phosphatase rises during fracture healing and peaks at 2-3 months 3
- Concerning if: Persistent elevation beyond 3-4 months or disproportionately high
Workup needed:
- Repeat alkaline phosphatase with fractionation (bone-specific vs liver) at 3 months post-fracture
- If persistently elevated, rule out Paget's disease, osteomalacia, or occult malignancy
- Check calcium, phosphate, PTH, 25(OH)D levels
Why Not Continue or Switch Bisphosphonates
Bisphosphonates have failed this patient. The evidence shows:
- She fractured her hip while taking Actonel (risedronate), demonstrating inadequate fracture protection 3
- Switching to another bisphosphonate (e.g., zoledronic acid) offers no proven advantage after treatment failure
- Anabolic therapy shows superior fracture reduction compared to bisphosphonates in high-risk patients 1
- The VERO trial demonstrated teriparatide reduces fractures more than risedronate in very high-risk women 1
Cardiovascular Risk and Osteoporosis Therapy
Important nuance: While this patient has significant cardiovascular disease (CAC 292, AAA), neither bisphosphonates nor denosumab accelerate vascular calcification 4, 5, 6. Recent evidence shows:
- Alendronate may actually reduce cardiovascular mortality and MI risk in hip fracture patients 5
- Denosumab does not affect progression of coronary or aortic calcification 4
- The cardiovascular concerns are specific to romosozumab due to sclerostin inhibition 2, 7
Therefore, teriparatide or abaloparatide followed by denosumab is cardiovascularly safe in this patient.
Common Pitfalls to Avoid
- Do not delay anabolic therapy thinking you should "optimize" bisphosphonate dosing first—she already failed bisphosphonates
- Do not use romosozumab despite its efficacy—her cardiovascular risk profile makes it contraindicated
- Do not stop denosumab once started without immediate transition to another antiresorptive—this causes dangerous rebound fractures 1
- Do not assume elevated alkaline phosphatase is only from fracture healing—follow up to rule out other pathology
- Do not forget calcium and vitamin D supplementation—essential for all osteoporosis therapy 8
Monitoring Plan
- Bone turnover markers (CTX, P1NP) at 3-6 months to confirm anabolic response 2
- BMD by DXA at 12-24 months to assess treatment response
- Repeat alkaline phosphatase at 3 months post-fracture with fractionation
- Calcium levels 16+ hours after teriparatide/abaloparatide dose if checking 2
- Fracture risk reassessment after completing 2 years of anabolic therapy before transitioning to denosumab